Anti-PD-1 Therapy plus Chemotherapy and/or Bevacizumab as Second Line or later Treatment for Patients with Advanced Non-Small Cell Lung Cancer

Zhang, Fan; Huang, Di; Li, Tao; Zhang, Sujie; Wang, Jinliang; Zhang, Yuzi; Wang, Guoqiang; Zhao, Zhengyi; Ma, Junxun; Wang, Lijie; Sun, Danyang; Cui, Pengfei; Cai, Shangli; Jiao, Shunchang; Zhao, Lei; Hu, Yi

doi:10.7150/jca.37966



International Journal of Biological Sciences

International Journal of Medical Sciences

Theranostics

Journal of Genomics

Nanotheranostics

Global reach, higher impact

Full Text | PDF

J Cancer 2020; 11(3):741-749. doi:10.7150/jca.37966 This issue Cite

Research Paper

Anti-PD-1 Therapy plus Chemotherapy and/or Bevacizumab as Second Line or later Treatment for Patients with Advanced Non-Small Cell Lung Cancer

Fan Zhang^1*, Di Huang^2,1*, Tao Li^1*, Sujie Zhang¹, Jinliang Wang¹, Yuzi Zhang³, Guoqiang Wang³, Zhengyi Zhao³, Junxun Ma¹, Lijie Wang¹, Danyang Sun¹, Pengfei Cui¹, Shangli Cai³, Shunchang Jiao¹, Lei Zhao^4✉, Yi Hu^1,2✉

1. Department of Oncology, Chinese PLA General Hospital, PLA School of Medicine, Beijing, People's Republic of China
2. School of medicine, Nankai University, Tianjin, People's Republic of China
3. The Medical Department, 3D Medicines Inc., Shanghai, People's Republic of China
4. National Clinical Research Center for Normal Aging and Geriatric & The Key Lab of Normal Aging and Geriatric, Institute of Geriatric, PLA General Hospital, Beijing, People's Republic of China
*Three authors contributed equally to this work.

✉ Corresponding authors: Yi Hu, Department of Oncology, Chinese PLA General Hospital, 28 Fuxing Road, Haidian, Beijing 100853, P.R. China. School of medicine, Nankai University, Tianjin, People's Republic of China. Tel: +86-13911031186, Fax: +86- 010- More

Citation:

Zhang F, Huang D, Li T, Zhang S, Wang J, Zhang Y, Wang G, Zhao Z, Ma J, Wang L, Sun D, Cui P, Cai S, Jiao S, Zhao L, Hu Y. Anti-PD-1 Therapy plus Chemotherapy and/or Bevacizumab as Second Line or later Treatment for Patients with Advanced Non-Small Cell Lung Cancer. J Cancer 2020; 11(3):741-749. doi:10.7150/jca.37966. https://www.jcancer.org/v11p0741.htm

Other styles

Abstract

Immune checkpoint inhibitor combination therapy exhibited outstanding efficacy in first line setting for advanced non-small cell lung cancer (aNSCLC) patients. However, whether PD-1 inhibitor combined treatment is effective in second line or later setting remains unknown. Therefore, we retrospectively evaluated the efficacy of combined therapy of PD-1 inhibitor with chemotherapy and/or bevacizumab compared to PD-1 inhibitor alone for aNSCLC patients in second line or later setting. Patients with aNSCLC who have received anti-PD-1 based therapy between 2015 and 2017 were screened, and 55 patients were ultimately included and divided into the monotherapy group (N=33) and the combination group (N=22). Patients treated with combination therapy exhibited superior PFS versus those treated with monotherapy (median PFS, 7.5 months vs 3.3 months; hazard ratio 0.28; 95% CI, 0.14-0.56; P<0.001). Objective response rate and disease control rate were 31.8% (7/22) and 95.5% (21/22) in the combination group and 10.0% (3/30) and 46.7% (14/30) in the monotherapy group, respectively (ORR, P=0.075; DCR, P<0.001). Five patients (22.7%) experienced grade 3-4 adverse events in the combination group and two patients (6.1%) in the monotherapy group. Taken together, our results indicated that for NSCLC patients who had failed on the first-line or later treatment, PD-1 inhibitor in combination with chemotherapy and/or bevacizumab might be a favorable treatment option. These findings warrant further validation in prospective studies.

Keywords: immune checkpoint inhibitor, combination therapy, non-small cell lung cancer

Citation styles

APA

Zhang, F., Huang, D., Li, T., Zhang, S., Wang, J., Zhang, Y., Wang, G., Zhao, Z., Ma, J., Wang, L., Sun, D., Cui, P., Cai, S., Jiao, S., Zhao, L., Hu, Y. (2020). Anti-PD-1 Therapy plus Chemotherapy and/or Bevacizumab as Second Line or later Treatment for Patients with Advanced Non-Small Cell Lung Cancer. Journal of Cancer, 11(3), 741-749. https://doi.org/10.7150/jca.37966.

ACS

Zhang, F.; Huang, D.; Li, T.; Zhang, S.; Wang, J.; Zhang, Y.; Wang, G.; Zhao, Z.; Ma, J.; Wang, L.; Sun, D.; Cui, P.; Cai, S.; Jiao, S.; Zhao, L.; Hu, Y. Anti-PD-1 Therapy plus Chemotherapy and/or Bevacizumab as Second Line or later Treatment for Patients with Advanced Non-Small Cell Lung Cancer. J. Cancer 2020, 11 (3), 741-749. DOI: 10.7150/jca.37966.

NLM

CSE

Zhang F, Huang D, Li T, Zhang S, Wang J, Zhang Y, Wang G, Zhao Z, Ma J, Wang L, Sun D, Cui P, Cai S, Jiao S, Zhao L, Hu Y. 2020. Anti-PD-1 Therapy plus Chemotherapy and/or Bevacizumab as Second Line or later Treatment for Patients with Advanced Non-Small Cell Lung Cancer. J Cancer. 11(3):741-749.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.